Financial Gravity Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Financial Gravity Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Hold	0	–	–	–	1446
2023 Q3	–	Sell	-36	Closed	-$1.28K	–	1176
2023 Q2	$10	Sell	36 -1	-3%	-$41	﹤0.01%	1537
2023 Q1	$6	Sell	37 -8	-18%	-$360	﹤0.01%	913
2022 Q4	$12	Sell	45 -165	-79%	-$10.7K	﹤0.01%	1358
2022 Q3	$10	Buy	+210	New	+$15.5K	﹤0.01%	765

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Financial Gravity Asset Management's MRTX Position: Q4 2023 in Review

Financial Gravity Asset Management held its Mirati Therapeutics, Inc. Common Stock (MRTX) position steady in Q4 2023 at 0 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #1446.

Financial Gravity Asset Management first reported a position in MRTX in Q3 2022 and has held it in 4 quarters since. The position peaked at $12 in Q4 2022. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Financial Gravity Asset Management held 0 shares of Mirati Therapeutics, Inc. Common Stock worth $17 as of Q4 2023.
Financial Gravity Asset Management left its Mirati Therapeutics, Inc. Common Stock share count unchanged in Q4 2023.
Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of Financial Gravity Asset Management's portfolio in Q4 2023, its #1446 holding.
Financial Gravity Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2022 and has held it in 4 quarters since.
Financial Gravity Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $12 in Q4 2022.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Financial Gravity Asset Management's 13F filing for Q4 2023, filed 15 Feb 2024.